Guest Post: Withdrawing Life-Prolonging Treatment in the Patient’s Best Interests: The Implications of Briggs

Guest Post: Jenny Kitzinger, Celia Kitzinger and Jakki Cowley Paper:  When ‘Sanctity of Life’ and ‘Self-Determination’ clash In a recent landmark judgment in the Court of Protection (Briggs v Briggs [2016] EWCOP 53), a judge authorised withdrawal of life-prolonging treatment from a minimally conscious patient with potential for further recovery.  Our article in the Journal of […]

Read More…

Is Hope a Virtue?

By Iain Brassington It’s perfectly understandable that hope should have featured so prominently in the coverage of the Charlie Gard case; each proposal is presented as offering fresh hope, each reversal presented as dashing hopes.  In either case, hope is something presented as desirable.  A bit more deeply, hope is one of the Theological Virtues, and […]

Read More…

Never Let an Ill Child Go to Waste

By Iain Brassington The Charlie Gard saga is one about which I’ve been reluctant to say anything, not least because plenty of other people have said plenty elsewhere.  Sometimes they add heat, and sometimes they add light. Beneath everything, the story is fairly simple: a small child is terribly ill; it is agreed by medical opinion […]

Read More…

Not Just About Consent: The Ethical Dimensions of Research Methodology Knowledge in IRBs

Guest Post: Sarah Wieten The recent article, “Some Social Scientists Are Tired of Asking for Permission” in the New York Times inspired a great deal of debate about the role of institutional research ethics board (IRB) oversight in social science, which some argue is in most cases unlikely to involve significant harm to participants. While […]

Read More…

“NOW’s interest in pharmaceutical gender equity seems to have disappeared with its funding.”

There’s a remarkable piece on the Hastings Center’s blog by Alycia Hogenmiller about a drug called Addyi.  Addyi is a drug that doesn’t work to treat a condition that doesn’t exist, pushed by campaigners who are actually industry shills. Sprout Pharmaceuticals, run by Cindy and Robert Whitehead, was determined to obtain regulatory approval for flibanserin […]

Read More…

What’s the Point of Professional Ethical Codes?

For a few reasons, I’ve been thinking a bit over the last few months about professionalism and professional codes.  In fact, that’s the topic that’s attracted most of my attention here since… oooh, ages ago.  I find the idea of a code of professional ethics troubling in many ways, but also fascinating.  And one of […]

Read More…

No Pain, All Gain: The Case for Farming Organs in Brainless Humans

Guest post by Ruth Stirton, University of Sussex (@RuthStirton) and David Lawrence, Newcastle University (@Biojammer) It is widely acknowledged that there is a nationwide shortage of organs for transplantation purposes.  In 2016, 400 people died whilst on the organ waiting list.  Asking for donors is not working fast enough.  We should explore all avenues to […]

Read More…

Appealing to the Crowd: Ethical Justifications in Canadian Medical Crowdfunding Campaigns

Guest Post: Jeremy Snyder Paper:Appealing to the crowd: ethical justifications in Canadian medical crowdfunding campaigns Medical crowdfunding is a practice where users take advantage of the power of social networks to raise funds related to medical needs from friends, family, and strangers by sharing fundraising appeals online. Popular venues include GiveForward, GoFundMe, and YouCaring, among […]

Read More…

A Plutocratic Proposal: An Ethical Way for Rich Patients to Pay for a Place on a Clinical Trial

Guest Post: Alexander Masters and Dominic Nutt Paper: A Plutocratic Proposal: an ethical way for rich patients to pay for a place on a clinical trial Is it ethically possible to fund a clinical trial by charging the participants?  We believe we have discovered a way to do it.  Our suggested method has, as far as […]

Read More…